eMedicine Specialties > Infectious Diseases > Viral Infections

Enteroviruses

Author: Smeeta Sinha, MD, Staff Physician, Department of Dermatology, UMDNJ-New Jersey Medical School
Coauthor(s): Rajendra Kapila, MD, MBBS, Associate Professor, Department of Medicine, UMDNJ, New Jersey Medical School; Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School; Pratibha Dua, MD, MBBS, Staff Physician, Department of Internal Medicine, The Brooklyn Hospital Center; Leonard B Berkowitz, MD, Chief, Divisions of Infectious Diseases and HIV/AIDS Services, Brooklyn Hospital Center; Clinical Assistant Professor, Department of Medicine, State University of New York at Brooklyn
Contributor Information and Disclosures

Updated: Aug 1, 2006

Introduction

Background

Enteroviruses belong to the Picornaviridae family of viruses and are further organized into the subgenera polioviruses, coxsackieviruses (groups A and B), and echoviruses. More than 60 serotypes have been identified, but only the first 61 are classified; 3 serotypes comprise the polioviruses, 23 serotypes comprise coxsackievirus group A, 6 serotypes comprise coxsackievirus group B, and 29 serotypes comprise the echoviruses. More recently identified enteroviruses are not included in the original classification; serotypes 68-71 are known as the newer enteroviruses.

The enteroviruses are icosahedral nonenveloped viruses that are approximately 30 nm in diameter. The genome is made of a single-stranded linear molecule of RNA. Enteroviruses resist lipid solvents and tolerate a wide range of pH and temperature. They are inactivated at temperatures of more than 50°C but remain infectious at refrigerator temperatures.

Enteroviruses cause a wide range of infections. Poliovirus infections can be subclinical or can cause mild illness, aseptic meningitis, or poliomyelitis. Coxsackievirus infection is the most common cause of viral heart disease. Group A viruses cause flaccid paralysis, while group B viruses cause spastic paralysis. Other diseases associated with coxsackievirus infections include hand-foot-and-mouth (HFM) disease and hemorrhagic conjunctivitis, caused by group A, while group B coxsackievirus is associated with herpangina, pleurodynia, myocarditis, pericarditis, and meningoencephalitis. Aseptic meningitis and colds are associated with both groups. Echovirus infections range from the common cold and fever to aseptic meningitis and acute hemorrhagic conjunctivitis (AHC).

Pathophysiology

Enteroviruses are transmitted predominantly via the fecal/oral route, although respiratory-oral spread and spread by fomites are also possible. Upon entry into the oropharynx, the virus replicates in submucosal tissues of the distal pharynx and alimentary tract. Viral particles are shed in the feces and in upper respiratory secretions for days prior to symptom onset. The average incubation period is 3-10 days, during which the virus migrates to regional lymphoid tissue and replicates. Minor viremia results, which is associated with the onset of symptoms and viral spread to the reticuloendothelial system (spleen, liver, bone marrow). Dissemination to target organs follows, and viral replication in target organs causes major viremia with secondary seeding of the CNS. Target organs include the skin, heart, and CNS.

The neuropathy of paralytic diseases caused by enteroviruses is due to direct cellular destruction. Neuronal lesions occur mainly in anterior horn cells of the spinal cord. The 3 serotypes of poliovirus all bind to the cell surface receptor CD155.

Intact humoral immunity is required for the control and eradication of enteroviral disease. Immunoglobulin (Ig) A, IgM and IgG are all produced in response to Enterovirus infection.

Frequency

United States

Nonpolio enteroviruses are responsible for 10-20 million symptomatic infections per year. The prevalence is higher in southern areas than in northern areas. Between 2002 and 2004, echoviruses 9 and 30 were the most commonly reported Enterovirus serotypes in the United States. AHC was first recognized in the United States in 1981 during an epidemic in Florida; few cases have been reported since.

International

Enteroviruses are distributed worldwide and are influenced by season and climate. Infections occur in summer and early fall in temperate areas, while tropical and semitropical areas bear the brunt all year.

AHC occurs as epidemics in tropical countries during the hot and rainy season. It was first recognized in 1969 in Ghana and Indonesia. AHC is an epidemic in India and the Far East.

The worldwide prevalence of poliomyelitis has decreased significantly because of improved economic conditions and availability of vaccines. The last case of wild polio in the Americas occurred in Peru in 1991. In 1994, the World Health Organization declared polio eradicated from the Western Hemisphere. Polio remains a significant disease in the developing world, and, in 2003, 6 endemic countries were identified: Afghanistan, Egypt, India, Niger, Nigeria, and Pakistan. Between 2002 and 2005, wild-type poliovirus imported from these nations was recognized in 21 previously polio-free countries.

Mortality/Morbidity

  • Myopericarditis is associated with a mortality rate of 0-4%. Myocarditis carries a higher mortality rate than pericarditis does. Additionally, murine model studies have suggested that a deficiency of complement receptors 1 and 2 leads to increased morbidity in coxsackie B3 infections, including myocarditis, dilated cardiomyopathy, and fibrosis.
  • Prior to the vaccine era, the mortality rate in polio epidemics was 5-7%.
  • The overall risk of oral poliovirus vaccine (OPV)–related disease is estimated to be 1 case per 2.6 million doses of OPV. In 1999, the inactivated poliovirus vaccine (IPV) was incorporated into the routine polio vaccination schedule; the incidence of vaccine-associated polio has subsequently decreased.

Sex

  • The male-to-female ratio of myopericarditis is 2:1. The risk of cardiac involvement is higher during pregnancy and immediately postpartum.
  • The prevalence of polio infection is equal in boys and girls, although paralysis is more common in boys. Among adults, women are at increased risk of infection and the postpolio syndrome compared with men.
  • Aseptic meningitis is approximately twice as common in boys as it is in girls.

Age

  • Enterovirus infections are most common in young children. Herpangina primarily affects children aged 3 months to 16 years. Poliomyelitis is observed in children younger than 15 years. Aseptic meningitis due to Enterovirus infection is more common in infants than in adults. Most cases of pleurodynia occur in children and adults younger than 30 years.
  • Myopericarditis is most prevalent in young adults, especially those who are physically active. AHC is most prevalent in adults aged 20-50 years.
  • Neonates are at high risk for severe sepsis due to Enterovirus infections.

Clinical

History

  • Polio
    • Patients with abortive polio present with symptoms similar to those of other viral infections, including fever, headache, sore throat, loss of appetite, vomiting, and abdominal pain. Neurologic symptoms are typically not reported.
    • The symptoms of nonparalytic polio are similar to those of abortive polio but are more intense. Patients report stiffness of the posterior muscles of the neck, trunk, and limbs.
    • Paralytic polio presents similarly to nonparalytic polio, along with weakness of one or more muscle groups. Exercise increases the severity of paralytic polio, especially during the first 3 days of major illness. Intramuscular injections or skeletal muscle injury predisposes to localization of polio to that extremity (termed provocation poliomyelitis).
      • Spinal: Patients have a prolonged prodrome, with features of aseptic meningitis followed in 1-2 days by weakness and, eventually, paralysis.
      • Bulbar: Cranial nerves are involved, most commonly IX, X, and XII. Tonsillectomy increases the risk of bulbar polio. Patients are unable to swallow smoothly. They accumulate pharyngeal secretions; have a nasal twang to the voice; and develop paralysis of vocal cords, causing hoarseness, aphonia, and, eventually, asphyxia.
      • Polioencephalitis: This form is principally reported in children. Unlike in other forms of polio, seizures are common and paralysis may be spastic.
  • Pleurodynia
    • Group B coxsackieviruses, particularly B3 and B5, are the most important causes of epidemic pleurodynia. Multiple family members may be affected.
    • Pleurodynia manifests with a sudden onset of fever accompanied by muscular pain in the chest and abdomen. The pain is spasmodic in nature, with spasms lasting 15-30 minutes and worsening during inspiration or coughing. This paroxysmal pain is characteristically associated with fever, peaking within 1 hour after onset of each paroxysm and subsiding with the subsequent paroxysm. Headache, nausea, and vomiting are also frequently reported.
  • Myopericarditis
    • Enteroviruses do not infect the pericardium without myocardial involvement, but signs of either myocarditis or pericarditis supervene.
    • Neonatal infections typically develop within the first week of life, and involvement is predominantly myocardial. In contrast, older children and adults usually present with symptoms of pericarditis.
    • The typical presentation is shortness of breath, chest pain, and fever approximately 1-2 weeks following an upper respiratory infection. Chest pain may be dull or sharp; it is worsened by inspiration and may improve with sitting and leaning forward. It can be differentiated from angina by lack of response to nitroglycerin.
  • Acute hemorrhagic conjunctivitis
    • This highly contagious ocular infection can cause large-scale epidemics. AHC was first described in 1969. Enterovirus 70 is the most common etiology in epidemics. Coxsackievirus A24 causes a similar disease. AHC was initially recognized in Ghana and Indonesia and is epidemic in India and the Far East.
    • The mode of transmission is from finger or fomite to eye. AHC is highly contagious, and crowding and unsanitary conditions favor spread.
    • Onset is abrupt, and the most common symptoms include ocular pain and burning, swelling of the eyelids, and the sensation of a foreign body in the eye. Patients may also experience photophobia and watery discharge. The other eye becomes involved a few hours after the first eye.
    • Nonspecific symptoms such as fever, malaise, and headache may be present. The symptoms typically improve by the second or third day of infection, and recovery is complete within 7-10 days.
  • Nonspecific febrile illness
    • This is the most common presentation of Enterovirus infection.
    • Nonspecific febrile illness manifests with sudden fever (temperature, 101-104°F). Fever may last for as long as a week and may show a biphasic pattern.
    • Patients may report myalgia, headache, sore throat, nausea, vomiting, mild abdominal discomfort, and diarrhea.
  • Aseptic meningitis
    • The clinical presentation of aseptic meningitis varies greatly among patients. Prodromal symptoms include fever, chills, headache, photophobia, and nuchal rigidity. Rash and upper respiratory symptoms are also common.
    • Fever and meningeal signs subside within 2-7 days.
    • Coxsackievirus B and echoviruses are the most common causes of aseptic meningitis. Enterovirus 71 causes a particularly aggressive CNS infection.
  • Herpangina
    • Symptoms include sudden onset of fever, sore throat, and difficulty swallowing, followed one day later by a painful vesicular eruption of the oral mucosa. The posterior pharynx and tonsils may also be involved.
    • Patients may report anorexia, malaise, irritability, headache, backache, and diarrhea. Symptoms resolve in 3-4 days.
  • Hand-foot-and-mouth disease
    • This is mainly a disease of children; most patients are younger than 10 years. Epidemics of HFM disease occur approximately every 3 years.
    • Coxsackievirus A16 is the most common etiologic agent, although Enterovirus 71 and numerous other Coxsackievirus serotypes may also cause the disease.
    • Following an incubation period of 3-6 days, patients experience prodromal symptoms such as fever, cough, sore throat, malaise, and anorexia. The prodrome lasts from 12-36 hours, and, subsequently, patients report vesicular eruptions of the hands, feet, and oral cavity. This may cause decreased oral intake in young children. The lesions self-resolve within 5-7 days.
    • Infection with Enterovirus 71 may be accompanied by severe neurologic disease including encephalitis, meningitis, and poliolike paralysis.
  • Encephalitis
    • This is an uncommon manifestation of Enterovirus infection.
    • Echovirus 9 is the most common etiologic agent.

Physical

Physical examination findings in Enteroviral disease vary greatly depending on the type of illness caused by each etiologic agent.

  • Nonspecific febrile illness: Physical findings are those of general viral illness, and mild pharyngeal erythema or conjunctivitis may be present.
  • Pleurodynia: Paroxysmal chest pain is characteristic, and the initial paroxysm is usually the most severe. During paroxysms, respirations are rapid and shallow and patients look ill. The pain is reproducible, and patients appear healthy between paroxysms of pain. Auscultation may reveal a pleural friction rub.
  • Myopericarditis: A pericardial friction rub is transient, if present. Signs of congestive heart failure are present in 20% of cases.
  • AHC: The hallmark physical findings include ocular erythema and subconjunctival hemorrhage. Palpebral edema, chemosis, and ocular discharge may also be noted. Preauricular lymphadenopathy is an associated finding in AHC.
  • Aseptic meningitis: Meningeal signs (nuchal rigidity, bulging fontanelles in infants) may be present, along with positive Kernig and/or Brudzinski sign. Some patients develop a rash.
  • Herpangina: Examination of the oral mucosa reveals punctate macular lesions that evolve into vesicles and eventually ulcerate. The most common site of involvement is the anterior tonsillar pillar and soft palate. The lesions are tender and subside within one week.
  • HFM disease: Vesicular lesions develop on the hands and feet and in the oral cavity. Hands are involved more commonly than feet. The vesicles appear gray and are surrounded by erythematous rings. Lesions are tender and resemble those of herpes simplex or varicella zoster infection. They resolve in approximately one week.
  • Poliomyelitis
    • Nonparalytic polio: Signs of meningeal irritation are present, and patients may have positive Kernig and Brudzinski signs. In infants, the head drop sign can be elicited.
    • Paralytic polio: In early stage disease, reflexes are normally active. A change in the character of reflexes precedes paralysis by 12-24 hours. Superficial reflexes are the first to decrease, followed in 8-24 hours by loss of deep tendon reflexes. The resultant paralysis is flaccid and characteristically asymmetric in distribution. Proximal limb muscles are involved more than distal muscles. The lower extremities are affected more commonly than the upper extremities.
  • Orchitis and epididymitis: Enteroviruses are the most common viral cause of orchitis. Orchitis is usually associated with pleurodynia.

Causes

  • The most common mode of transmission of enteroviruses is by the fecal-oral route. Poor sanitation, low socioeconomic status, and crowded living conditions all facilitate the spread of infection.

More on Enteroviruses

Overview: Enteroviruses
Differential Diagnoses & Workup: Enteroviruses
Treatment & Medication: Enteroviruses
Follow-up: Enteroviruses
References

References

  1. Agre JC, Rodriquez AA, Tafel JA. Late effects of polio: critical review of the literature on neuromuscular function. Arch Phys Med Rehab. Oct 1991;72(11):923-31.

  2. Aston JW Jr. Post-polio syndrome. An emerging threat to polio survivors. Postgrad Med. Jul 1992;168(1):249-56,260.

  3. Barnard DL. Current status of anti-picornavirus therapies. Curr Pharm Des. 2006;12(11):1379-90.

  4. Bartfeld H, Ma D. Recognizing post-polio syndrome. Hosp Pract (Off Ed). May 15 1996;31(5):95-7, 101-3, 107 passim. [Medline].

  5. Cardosa MJ, Perera D, Brown BA. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis. Apr 2003;9(4):461-8.

  6. Centers for Disease Control and Prevention (CDC). Enterovirus surveillance--United States, 2002-2004. MMWR Morb Mortal Wkly Rep. Feb 17 2006;55(6):153-6.

  7. Conrad DA, Jenson HB. New recommendations for poliovirus vaccination. Combination regimen captures best effects of available vaccines. Postgrad Med. Nov 1997;102(5):45-8, 51-3, 59-60 passim. [Medline].

  8. Desmond RA, Accortt NA, Talley L. Enteroviral meningitis: natural history and outcome of pleconaril therapy. Antimicrob Agents Chemother. Jul 2006;50(7):2409-14.

  9. Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis. Feb 1997;175 Suppl 1:S286-92.

  10. Fairweather D, Frisancho-Kiss S, Njoku DB. Complement receptor 1 and 2 deficiency increases coxsackievirus B3-induced myocarditis, dilated cardiomyopathy, and heart failure by increasing macrophages, IL-1beta, and immune complex deposition in the heart. J Immunol. Mar 15 2006;176(6):3516-24.

  11. Honeyman M. How robust is the evidence for viruses in the induction of type 1 diabetes?. Curr Opin Immunol. Dec 2005;17(6):616-23.

  12. Hsiung GD, Wang JR. Enterovirus infections with special reference to enterovirus 71. J Microbiol Immunol Infect. Mar 2000;33(1):1-8. [Medline].

  13. Jubelt B, Agre JC. Characteristics and management of postpolio syndrome. JAMA. Jul 26 2000;284(4):412-4. [Medline].

  14. Lonnrot M, Korpela K, Knip M, et al. Enterovirus infection as a risk factor for beta-cell autoimmunity in a prospectively observed birth cohort: the Finnish Diabetes Prediction and Prevention Study. Diabetes. Aug 2000;49(8):1314-8. [Medline].

  15. Melnick JL. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. Fields Virology. 1996;3rd ed. Philadelphia, Pa: Lippincott-Raven:655-712.

  16. Modlin JF. Introduction to Enteroviruses. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 6th ed. New York: Churchill Livingstone; 2005..

  17. Patriarca PA, Foege WH, Swartz TA. Progress in polio eradication. Lancet. Dec 11 1993;342(8885):1461-4.

  18. Pesonen E, Andsberg E, Ohlin H. Dual role of infections as risk factors for coronary heart disease. Atherosclerosis. Jun 14 2006.

  19. Pevear DC, Tull TM, Seipel ME, Groarke JM. Activity of pleconaril against enteroviruses. Antimicrob Agents Chemother. Sep 1999;43(9):2109-15. [Medline].

  20. Racaniello VR. One hundred years of poliovirus pathogenesis. Virology. Jan 5 2006;344(1):9-16.

  21. Roivainen M. Enteroviruses and myocardial infarction. Am Heart J. Nov 1999;138(5 Pt 2):S479-83. [Medline].

  22. Rotbart HA, Webster AD. Treatment of potentially life-threatening enterovirus infections with pleconaril. Clin Infect Dis. Jan 15 2001;32(2):228-35. [Medline].

  23. Sawyer MH. Enterovirus infections: diagnosis and treatment. Pediatr Infect Dis J. Dec 1999;18(12):1033-9; quiz 1040. [Medline].

  24. Skarsvik S, Puranen J, Honkanen J. Decreased in vitro type 1 immune response against coxsackie virus B4 in children with type 1 diabetes. Diabetes. Apr 2006;55(4):996-1003.

  25. Thorsteinsson G. Management of postpolio syndrome. Mayo Clin Proc. 1997Jul;72(7):627-38. [Medline].

  26. WHO. Resurgence of wild poliovirus type 1 transmission and effect of importation into polio-free countries, 2002-2005. Wkly Epidemiol Rec. Feb 17 2006;81(7):63-8.

  27. Webster AD. Pleconaril--an advance in the treatment of enteroviral infection in immuno-compromised patients. J Clin Virol. Jan 2005;32(1):1-6.

  28. Zaoutis T, Klein JD. Enterovirus infections. Pediatr Rev. Jun 1998;19(6):183-91. [Medline].

Further Reading

Keywords

Enterovirus, enteroviral infections, Bornholm disease, Bornholm's disease, epidemic myalgia, Sylvest's disease, Sylvest disease, devil's grip, polio, poliovirus, coxsackievirus group A, coxsackievirus group B, echovirus, aseptic meningitis, poliomyelitis, viral heart disease, hand foot and mouth disease, hand-foot-and-mouth disease, HFM disease, hemorrhagic conjunctivitis, herpangina, pleurodynia, myocarditis, pericarditis, meningoencephalitis, common cold, aseptic meningitis, acute hemorrhagic conjunctivitis, AHC, viremia, myopericarditis, abortive polio, nonparalytic polio, paralytic polio

Contributor Information and Disclosures

Author

Smeeta Sinha, MD, Staff Physician, Department of Dermatology, UMDNJ-New Jersey Medical School
Smeeta Sinha, MD is a member of the following medical societies: Alpha Omega Alpha, Phi Beta Kappa, and Sigma Xi
Disclosure: Nothing to disclose.

Coauthor(s)

Rajendra Kapila, MD, MBBS, Associate Professor, Department of Medicine, UMDNJ, New Jersey Medical School
Rajendra Kapila, MD, MBBS is a member of the following medical societies: American College of Physicians, American Medical Association, Infectious Diseases Society of America, and Infectious Diseases Society of New Jersey
Disclosure: Nothing to disclose.

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Medicine, Professor of Pediatrics, Professor of Pathology, Professor of Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

Pratibha Dua, MD, MBBS, Staff Physician, Department of Internal Medicine, The Brooklyn Hospital Center
Pratibha Dua, MD, MBBS is a member of the following medical societies: American Medical Association
Disclosure: Nothing to disclose.

Leonard B Berkowitz, MD, Chief, Divisions of Infectious Diseases and HIV/AIDS Services, Brooklyn Hospital Center; Clinical Assistant Professor, Department of Medicine, State University of New York at Brooklyn
Leonard B Berkowitz, MD is a member of the following medical societies: American College of Physicians, American Society for Microbiology, Infectious Diseases Society of America, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Medical Editor

Mary Nettleman, MD, MS, Chair, Department of Medicine, Michigan State University
Mary Nettleman, MD, MS is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Central Society for Clinical Research, Infectious Diseases Society of America, and Society of General Internal Medicine
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Ronald A Greenfield, MD, Professor, Chief, Department of Internal Medicine, Section of Infectious Diseases, University of Oklahoma College of Medicine
Ronald A Greenfield, MD is a member of the following medical societies: American College of Physicians, American Federation for Medical Research, American Society for Microbiology, Central Society for Clinical Research, Infectious Diseases Society of America, Medical Mycology Society of the Americas, Phi Beta Kappa, Southern Society for Clinical Investigation, and Southwestern Association of Clinical Microbiology
Disclosure: Pfizer Honoraria Speaking and teaching; Gilead Honoraria Speaking and teaching; Ortho McNeil Honoraria Speaking and teaching; Wyeth Honoraria Speaking and teaching; Abbott Honoraria Speaking and teaching; Astellas Honoraria Speaking and teaching; Cubicin  Speaking and teaching

CME Editor

Eleftherios Mylonakis, MD, Clinical and Research Fellow, Department of Internal Medicine, Division of Infectious Diseases, Massachusetts General Hospital
Eleftherios Mylonakis, MD is a member of the following medical societies: American Association for the Advancement of Science, American College of Physicians, American Society for Microbiology, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

Chief Editor

Burke A Cunha, MD, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital
Burke A Cunha, MD is a member of the following medical societies: American College of Chest Physicians, American College of Physicians, and Infectious Diseases Society of America
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.